Nexeon MedSystems Announces Sale of Medi-Line, SA

Sales unlocks value for shareholders while advancing efforts to launch aVNS product Majority of $3.66M in net proceeds to be used to pay near-term debt maturities Company updates for 2019 Nexeon Medsystems, a medical device manufacturing company, has announced that it has closed on the sale of Medi-Line to a European private equity group.  The…

Details

Nexeon MedSystems Receives Grant Matching Funds from the Puerto Rico Science, Technology, and Research Trust

Dallas, TX, Nov. 05, 2018 — Nexeon MedSystems, Inc (”Nexeon”) (OTCQB: NXNN), a neurostimulation medical device company, announced that it has received grant matching funds from the Puerto Rico Science, Technology, and Research Trust (“Trust”). The National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH) recently awarded a $830,000…

Details

Nexeon Announces Submission for FDA Innovation Challenge

Dallas, TX, Oct. 11, 2018 — Nexeon MedSystems Inc (”Nexeon”) (OTCQB: NXNN), a neurostimulation medical device company, announces that it has submitted an application in response to the FDA Innovation Challenge: Devices to Prevent and Treat Opioid Use Disorder. Opioid Use Disorder (OUD), characterized by problematic symptoms of addiction to and withdrawal from opioids, is…

Details

ninds

Nexeon MedSystems Receives $830,000 grant from the National Institute of Neurological Disorders and Stroke

Dallas, TX, Sept. 25, 2018 — Nexeon MedSystems Inc (”Nexeon”) (OTCQB: NXNN), a neurostimulation medical device company, announced that it has received an $830,000 grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The grant award, received through its wholly-owned subsidiary Nexeon MedSystems Puerto Rico Operations…

Details

avns news

Nexeon Begins Clinical Study with Newly Developed Non-Invasive Vagus Nerve Stimulator

LIEGE, Belgium, Oct. 25, 2017 — Nexeon MedSystems Inc (OTCBB: NXNN) announced its completion of an initial series of clinical studies evaluating the utilization of transcutaneous auricular vagus nerve stimulation (aVNS) for the relief of paroxysmal atrial fibrillation.  The Company was previously awarded a €3.4M research grant in relation to this study from the Walloon…

Details